Since the introduction of BC molecular classification, systemic therapies are tailored according to BC heterogeneity (biomarkers as ER/PgR, Her2, Ki67) and aggressiveness (histological subtypes, histological grade, and tumor stage). Here, ERBB2 is linked to neoplasm.